Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome.
Nocturnal polyuria with repeated micturitions during the night is a clinically evident feature of obstructive sleep apnea syndrome (OSAS). These effects are reversed by continuous positive airway pressure (CPAP). There is some evidence that atrial natriuretic peptide (ANP) and catecholaminergic activity may be implicated in the pathogenesis of these symptoms. We studied these biochemical parameters in six patients with severe OSAS during two nights: the first (basal) in their normal conditions and the second during CPAP treatment. CPAP treatment reversed apnea episodes in all our patients. A significant (p less than 0.035) reduction of nocturnal urine volume (from 902 +/- 297 to 447 +/- 130 ml; mean +/- SD), sodium excretion (from 150 +/- 33 to 89 +/- 35 mEq/12 h), noradrenaline excretion (from 95 +/- 101 to 52 +/- 16 micrograms/g creatinine), noradrenaline plasma concentrations (from 325 +/- 96 to 259 +/- 75 pg/ml), ANP plasma concentrations (from 35 +/- 20 to 19 +/- 5 pg/ml) was observed during the night under CPAP application. These data suggest that in OSAS patients the high ANP plasma concentration is responsible for the observed elevated diuresis and sodium excretion. These effects are rapidly reversible, as they are reversed during the first CPAP treated night.
Baruzzi
A
A
Institute of Neurology, University of Bologna, Italy.
Riva
R
R
Cirignotta
F
F
Zucconi
M
M
Cappelli
M
M
Lugaresi
E
E
D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood*; D004837:Epinephrine / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood*; D010100:Oxygen / Q000097:blood; D011175:Positive-Pressure Respiration; D012891:Sleep Apnea Syndromes / Q000097:blood* / Q000628:therapy; D012894:Sleep Stages / Q000502:physiology*
D009320:Atrial Natriuretic Factor; D010100:Oxygen; D009638:Norepinephrine; D004837:Epinephrine